🍽️ eucatropine hydrochloride non-drug

AI Engines For more Details: PerplexityKagi LabsYou

  1. Pupil Dilation: Eucatropine hydrochloride acts by blocking the action of acetylcholine at muscarinic receptors in the iris sphincter muscle, causing pupil dilation (mydriasis). This effect allows eye care professionals to better visualize the internal structures of the eye during examinations or procedures.

  2. Reduced Tear Production: In addition to causing pupil dilation, eucatropine hydrochloride also decreases tear production (cycloplegia) by inhibiting the activity of the ciliary muscle. This helps to prevent the eye from accommodating, making it easier for eye care professionals to perform certain procedures.

  3. Temporary Blurred Vision: Pupil dilation induced by eucatropine hydrochloride can result in temporary blurred vision, sensitivity to light (photophobia), and difficulty focusing on nearby objects. These effects are usually temporary and resolve once the medication wears off and the pupils return to their normal size.

  4. Increased Intraocular Pressure: In some cases, eucatropine hydrochloride may cause a transient increase in intraocular pressure (IOP), which can be problematic for individuals with certain pre-existing eye conditions, such as glaucoma. Eye care professionals typically exercise caution when using eucatropine hydrochloride in patients at risk of elevated IOP.

  5. Systemic Effects: While eucatropine hydrochloride is primarily used as a topical ophthalmic solution and is not typically absorbed systemically in significant amounts, there is the potential for systemic side effects, especially if the medication is ingested accidentally or if excessive amounts are absorbed through mucous membranes.

  6. Contraindications: Eucatropine hydrochloride is contraindicated in individuals with a known hypersensitivity to anticholinergic medications and those with certain pre-existing eye conditions, such as narrow-angle glaucoma. It should be used with caution in patients with conditions that may be exacerbated by anticholinergic effects, such as urinary retention or gastrointestinal disorders.

  7. Adverse Reactions: Common adverse reactions associated with the use of eucatropine hydrochloride include stinging or burning upon instillation, dry mouth, blurred vision, and increased sensitivity to light. Serious adverse reactions are rare but may include allergic reactions, corneal abrasions, and acute angle-closure glaucoma in susceptible individuals.


Check for interactions on Supp.AI   |   πŸ“š PubMed Citations

Data Contradictions β€” Limits of Certainity

Impacted of eucatropine hydrochloride non-drug On Probiotics

Rank Probiotic Impact

Bacteria Impacted by eucatropine hydrochloride non-drug

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.


Taxonomy Rank Effect Citations Notation
Bilophila genus Decreases 👪 Source Study High Level Cause Brain Fog(Cognitive impairment)
Lacrimispora genus Decreases 👪 Source Study
Bacteroides genus Decreases 👪 Source Study
unclassified Robinsoniella no rank Decreases ⚗️ Source Study
unclassified Fusobacterium no rank Decreases ⚗️ Source Study
unclassified Negativicoccus no rank Decreases ⚗️ Source Study
Eggerthellales order Decreases ⚗️ Source Study
Bilophila wadsworthia species Decreases 📓 Source Study
Anaerofustis stercorihominis species Decreases ⚗️ Source Study
Asaccharospora irregularis species Decreases ⚗️ Source Study
Negativicoccus sp. S5-A15 species Decreases ⚗️ Source Study
Paraprevotella clara species Decreases ⚗️ Source Study
Slackia sp. NATTS species Decreases ⚗️ Source Study
Pseudoflavonifractor capillosus species Decreases ⚗️ Source Study
[Collinsella] massiliensis species Decreases ⚗️ Source Study
Parvibacter caecicola species Decreases ⚗️ Source Study
Lacrimispora saccharolytica species Decreases 📓 Source Study
Bacteroides uniformis species Decreases 📓 Source Study Infectious bacteria
Coriobacterineae suborder Decreases ⚗️ Source Study
Chlamydiae/Verrucomicrobia group superphylum Decreases ⚗️ Source Study

Impact of eucatropine hydrochloride non-drug on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Abdominal Aortic Aneurysm 0.1 0.1
ADHD 0 0
Allergic Rhinitis (Hay Fever) 0 0
Allergy to milk products 0 0
Alzheimer's disease 0.1 0.3 -2
Ankylosing spondylitis 0 0
Anorexia Nervosa 0 0
Antiphospholipid syndrome (APS) 0.1 -0.1
Asthma 0 0
Atrial fibrillation 0 0.1 0
Autism 0 0.1 0
Bipolar Disorder 0.1 0.1
Brain Trauma 0 0
Carcinoma 0.1 0 0
Celiac Disease 0 0.1 0
Cerebral Palsy 0 0
Chronic Fatigue Syndrome 0.2 0 0
Chronic Kidney Disease 0 0
Chronic Lyme 0 0
Colorectal Cancer 0 0
Constipation 0 0
COVID-19 0 0 0
Crohn's Disease 0.2 0 0
cystic fibrosis 0 0
Depression 0.4 0 0
Endometriosis 0 0
Epilepsy 0 0 0
Fibromyalgia 0 0
Functional constipation / chronic idiopathic constipation 0 0 0
Generalized anxiety disorder 0 0
Graves' disease 0 0
Halitosis 0 0
Hashimoto's thyroiditis 0 0.1 0
Hidradenitis Suppurativa 0.1 0.1
Histamine Issues,Mast Cell Issue, DAO Insufficiency 0 0
hyperglycemia 0 0
hypersomnia 0.1 -0.1
hypertension (High Blood Pressure 0 0.1 0
Hypoxia 0 0
IgA nephropathy (IgAN) 0 0
Inflammatory Bowel Disease 0 0 0
Insomnia 0 0 0
Intelligence 0 0
Intracranial aneurysms 0 0
Irritable Bowel Syndrome 0 0 0
Liver Cirrhosis 0.1 0.1 0
Long COVID 0 0.1 0
ME/CFS with IBS 0 0
ME/CFS without IBS 0.1 0 0
Metabolic Syndrome 0.1 0.2 -1
Mood Disorders 0.5 0 0
Multiple Sclerosis 0.1 0 0
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 0 0
Obesity 0.1 0 0
obsessive-compulsive disorder 0 0 0
Osteoarthritis 0 0
Osteoporosis 0 0 0
Parkinson's Disease 0.1 0.1
Polycystic ovary syndrome 0 0
primary biliary cholangitis 0 0
Psoriasis 0 0
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 0.1 0 0
Schizophrenia 0.2 0.2
scoliosis 0.1 -0.1
Sjögren syndrome 0 0
Sleep Apnea 0 0
Stress / posttraumatic stress disorder 0 0 0
Systemic Lupus Erythematosus 0.1 0.1
Tourette syndrome 0 0
Type 1 Diabetes 0.1 0.1
Type 2 Diabetes 0.1 0 0
Ulcerative colitis 0 0.2 0
Unhealthy Ageing 0.1 0.1

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.

Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.

Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.